Growth Hormone

Definition

The Growth Hormone category encompasses direct administration of recombinant human growth hormone (rhGH) and synthetic GH fragments that act directly on GH receptors. This is pharmacologically distinct from Category 5 (GH secretagogues): rather than stimulating the pituitary, these compounds bypass the endocrine axis entirely and deliver GH activity to peripheral receptors in liver, muscle, adipose tissue, and bone. The difference matters clinically — direct GH exerts broader, less regulated effects than physiologically pulsed endogenous GH produced in response to secretagogue stimulation.

Mechanism of Action

Recombinant hGH binds the GH receptor (a class I cytokine receptor) on hepatocytes to drive IGF-1 production, on myocytes to promote protein synthesis, and on adipocytes to stimulate lipolysis. In children with GH deficiency, it drives linear growth through cartilage and bone receptor activation. AOD-9604 is a modified fragment of the GH C-terminus (amino acids 176–191) that has been engineered to retain the lipolytic domain while omitting the IGF-1-stimulating and growth-promoting sequences. This makes AOD-9604 potentially useful for targeted fat loss without the full anabolic/mitogenic effects of rhGH.

Regulatory Status

Recombinant hGH (Genotropin, Norditropin, Humatrope, Nutropin, Omnitrope, and others) is FDA-approved for adult and pediatric GH deficiency, Turner syndrome, Prader-Willi syndrome, idiopathic short stature, and HIV-associated wasting. Off-label use for anti-aging, athletic performance, or body composition optimization is not FDA-approved and is specifically prohibited from compounding (rhGH is a Schedule III controlled substance). AOD-9604 completed Phase II trials for obesity and was not approved; it is available through compounding in the US.

Evidence Base

For approved GH deficiency indications, the evidence base is robust with decades of large clinical trials. Evidence for anti-aging and longevity applications in non-GH-deficient adults is largely extrapolated from the GHD treatment literature — a significant interpretive leap. Small longevity trials (e.g., TRIIM trial using rhGH + metformin + DHEA) are suggestive but underpowered for definitive conclusions. AOD-9604's Phase II obesity data was not sufficient for FDA approval, but mechanistic and small-trial evidence for focal adipose reduction is credible.